1. At a Glance
Founded in 1987 by Rajiv Gandhi (no, not that Rajiv Gandhi, calm down), Hester is India’s second-largest poultry vaccine maker and the undisputed king of goat & sheep vaccines. With 75% global market share in PPR vaccines and over 35% in poultry vaccines domestically, the company has a global footprint but Indian margins. Current story: sales growth crawling at 4–5%, but PAT in Q1 FY26 suddenly jumped 159% YoY. Investors scratching heads: “Are we a slow-growth defensive or a high-growth biotech rocket?” The market P/E of 48x says: maybe both, maybe neither.
2. Introduction
Animal healthcare is not exactly cocktail-party glamorous — nobody brags, “Bro, I’m into goat vaccines.” But Hester has quietly built itself into a powerhouse, supplying to 35+ countries, partnering with the Bill & Melinda Gates Foundation, OIE, and GALVmed, and serving farmers, poultry integrators, and livestock owners.
The company is basically an agri–pharma hybrid: when bird flu comes, Hester spikes; when cattle fall sick, Hester milks; when goats sneeze, Hester sneezes cash. Its product mix has also diversified — poultry vaccines (historical breadwinner), livestock vaccines (new driver), and a fledgling pet-care division.
But investors complain: topline growth is stuck in single digits, debt has crept up to ₹213 Cr, and ROE has slipped below 10%. Is this a case of an over-vaccinated stock? Or is the expansion cycle (Nepal, Tanzania, Kadi upgrades) about to finally kick in?
Let me ask you: would you pay SaaS multiples (48x) for a goat vaccine monopoly?
3. Business Model (WTF Do They Even Do?)
Hester runs four verticals:
- Poultry Healthcare (~48% of FY24 rev, down from 73% in FY22):
50+ poultry vaccines, diagnostic labs, mastitis programs. Hit badly in FY23 when high feed costs reduced bird placements. Recovery visible, but poultry still volatile. - Animal Healthcare (~43%):
Flagship division now. PPR vaccine monopoly, Goat Pox dominance, plus LSD (Lumpy Skin Disease) vaccines during outbreaks. Government immunisation programs (like PPR eradication by 2030) are big demand drivers. - Petcare (~9%):
Launched FY23. Growing 49% YoY. Pet supplements, gut health, joint care, grooming products. Basically, “Pedigree meets Zandu Balm.” - Exports (~14% of revenue):
Focus on Africa, Nepal, a bit of South America. India still 86%.
Capacity?
- Gujarat (Kadi): 6.25 bn doses
